NewsRoom Articles - BioMedWire (BMW)

TuesdaySep 15, 2026 10:00 am

Systemic Challenges in US Health Care Push Cancer Patients to Fly to China

For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba and Thailand in search of affordable, quality healthcare due to the persistent challenges plaguing the American health care system. Now the latest destination of choice for cancer treatment is China, according to a report by the WSJ (Wall Street Journal). CAR-T therapy, a new type of cancer treatment that bioengineers immune cells of a cancer patient in order to make them more potent against cancer, was developed in the U.S. However, the high cost of this treatment, together with the lengthy process of engineering the…

TuesdaySep 15, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell. The company is applying the BiTAC concept to both antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with an emphasis on solid tumors. With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value. VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a…

MondaySep 14, 2026 9:00 am

Earth Science Tech Inc.’s (ETST) Shareholders Approve Key Proposals in Annual Meeting

Earth Science Tech held its first annual meeting of stockholders, virtually, on August 31, 2026+ The shareholders authorized the Board to pursue a reverse stock split, if deemed necessary, to help the company uplist to a national exchange like Nasdaq or NYSE During the meeting, stockholders authorized the Board’s Independent Special Committee to negotiate the retirement of the Series B Preferred Stock, which would eliminate the current dual-class voting structure The shareholders also ratified the appointment of Semple, Marchal & Cooper LLP, as an independent registered public accounting firm, re-elected seven director nominees, and authorized a new non-dilutive executive compensation…

FridaySep 11, 2026 10:00 am

Rising Rates of the Uninsured Could Affect Every American

As more Americans become underinsured or uninsured as a result of rising health insurance premiums and the several changes that were passed in the Big Beautiful Act, the impacts of the rising numbers of the uninsured are likely to be felt by every American. Several healthcare professionals have sounded the alarm on this brewing issue. The Congressional Budget Office estimates that by 2034, about 16 million Americans will be uninsured. One of the factors contributing to people becoming uninsured is the H.R. 1 requirement for people on Medicaid to reconfirm their address and work situation at six-month intervals in order to remain on Medicaid. Safety net hospitals already operate on tight margins because…

FridaySep 11, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing the symptoms associated with its loss. Regentis Biomaterials’ GelrinC is designed to support the body’s natural cartilage-regeneration process through a gradual, controlled repair environment. Early clinical data has provided encouraging evidence for GelrinC, which already has approval in Europe, while an FDA-authorized pivotal trial is advancing its development toward potential U.S. approval. A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly,…

ThursdaySep 10, 2026 9:00 am

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed…

WednesdaySep 09, 2026 11:15 am

How Earth Science Tech Inc. (ETST) Is Building a Self-Sustaining Business on Strategic Vertical Integration and Dual-Segment Targeting

Earth Science Tech has made meaningful progress over the last few years, building a business anchored in a conglomerate model, infrastructure as a service, and end-to-end vertical integration The company is focused on the seamless integration of patient care through its operating businesses that offer telemedicine and telehealth infrastructure for consultations and third-party providers, compounding services, and fulfilment ETST has leveraged vertical integration to not only support the operations of its businesses but also tap into both B2B and B2C segments for revenue and growth Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine…

WednesdaySep 09, 2026 10:00 am

Expert Flags Hidden Crisis in the Way UTIs Are Diagnosed

For many women, UTIs are something they routinely experience. These usually start as a burning sensation or a sudden urge to use the bathroom. For some, there is a sudden onset of discomfort that they just cannot ignore. While many receive a dose of antibiotics after being told what’s bothering them “is just a UTI,” several questions remain in the mind of the woman. Was the sample used reliable? Did they receive the right diagnosis? Was the medical professional sure about what’s going on? These uncertainties put the issue beyond a medical one and expand it into a human issue as well. Giovanna Forte, a health tech entrepreneur…

TuesdaySep 08, 2026 11:15 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Builds Manufacturing, IND and Capital Foundation Ahead of Planned Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Investors in biotechnology often look for companies with a clear path toward clinical development, where regulatory preparation, manufacturing readiness and access to capital can help reduce execution risk. Onco-Innovations Ltd. is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company has strengthened its clinical foundation through manufacturing milestones, IND-enabling activities, strategic partnerships and a recent funding arrangement designed to support continued advancement of its oncology pipeline. For biotechnology investors, a…

TuesdaySep 08, 2026 9:00 am

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Systemic Challenges in US Health Care Push Cancer Patients to Fly to China

VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

Earth Science Tech Inc.’s (ETST) Shareholders Approve Key Proposals in Annual Meeting

Rising Rates of the Uninsured Could Affect Every American

Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

How Earth Science Tech Inc. (ETST) Is Building a Self-Sustaining Business on Strategic Vertical Integration and Dual-Segment Targeting

Expert Flags Hidden Crisis in the Way UTIs Are Diagnosed

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Builds Manufacturing, IND and Capital Foundation Ahead of Planned Clinical Translation

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search